Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination

Vaccine

Volumn 30, Issue 42, 2012, Pages 6047-6053

  Pakkanen, Sari H ^a,b   Kantele, Jussi M ^c   Kantele, Anu ^a,b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Paratyphoid fever; Salmonella Paratyphi; Salmonella Typhi Ty 21a; Typhoid fever; Typhoid vaccination

Indexed keywords

HOMING RECEPTOR; L SELECTIN; TYPHOID VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGY; LYMPH NODE; MALE; PARATYPHOID FEVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B; SALMONELLA PARATYPHI C; SALMONELLA TYPHI; SINGLE CELL ANALYSIS; TYPHOID FEVER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODY-PRODUCING CELLS; CROSS PROTECTION; CROSS REACTIONS; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INTEGRINS; INTESTINES; L-SELECTIN; LYMPH NODES; MALE; MIDDLE AGED; PARATYPHOID FEVER; POLYSACCHARIDES, BACTERIAL; RECEPTORS, LYMPHOCYTE HOMING; SALMONELLA PARATYPHI A; SKIN; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; YOUNG ADULT;

EID: 84865563962     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.051     Document Type: Article

References (47)

1. Shlim D.R., Schwartz E., Eaton M. Clinical importance of Salmonella Paratyphi A infection to enteric fever in Nepal. J Travel Med 1995, 2:165-168.
2. Vollaard A.M., Ali S., Widjaja S., Asten H.A., Visser L.G., Surjadi C., et al. Identification of typhoid fever and paratyphoid fever cases at presentation in outpatient clinics in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2005, 99:440-450.
3. Meltzer E., Sadik C., Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 2005, 12:275-281.
4. Maskey A.P., Day J.N., Phung Q.T., Thwaites G.E., Campbell J.I., Zimmerman M., et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006, 42:1247-1253.
5. Fangtham M., Wilde H. Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines. J Travel Med 2008, 15:344-350.
6. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid fever. Clin Infect Dis 2010, 50:241-246.
7. Sood S., Kapil A., Dash N., Das B.K., Goel V., Seth P. Paratyphoid fever in India: an emerging problem. Emerg Infect Dis 1999, 5:483-484.
8. Woods C.W., Murdoch D.R., Zimmerman M.D., Glover W.A., Basnyat B., Wolf L., et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006, 100:1063-1067.
9. Ochiai R.L., Wang X.Y., von Seidlein L., Yang J., Bhutta Z.A., Bhattacharya S.K., et al. Salmonella Paratyphi A rates, Asia. Emerg Infect Dis 2005, 11:1764-1766.
10. Connor B.A., Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005, 5:623-628.
11. Ekdahl K., de Jong B., Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J Travel Med 2005, 12:197-204.
12. Bhan M.K., Bahl R., Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005, 366:749-762.
13. Whitaker J.A., Franco-Paredes C., del Rio C., Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009, 16:46-52.
14. Meltzer E., Schwartz E. Enteric fever: a travel medicine oriented view. Curr Opin Infect Dis 2010, 5:432-437.
15. Chandel D.S., Chaudhry R., Dhawan B., Pandey A., Dey A.B. Drug-resistant Salmonella enterica serotype paratyphi A in India. Emerg Infect Dis 2000, 6:420-421.
16. Threlfall E.J., Fisher I.S., Berghold C., Gerner-Smidt P., Tschäpe H., Cormican M., et al. Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. Int J Antimicrob Agents 2003, 22:487-491.
17. Levine M.M., Ferreccio C., Black R.E., Lagos R., San Martin O., Blackwelder W.C. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007, 45:S24-S28.
18. Schwartz E., Shlim D.R., Eaton M., Jenks N., Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med 1990, 150:349-351.
19. Simanjuntak C.H., Paleologo F.P., Punjabi N.H., Darmowigoto R., Soeprawoto, Totosudirjo H., et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991, 338:1055-1059.
20. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990, 8:321-326.
21. Lundgren A., Kaim J., Jertborn M. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine 2009, 27:4529-4536.
22. Tagliabue A., Villa L., De Magistris M.T., Romano M., Silvestri S., Boraschi D., et al. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol 1986, 137:1504-1510.
23. Nishini R., Biselli R., Matricardi P.M., Fattorossi A., D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine 1993, 11:582-586.
24. Wahid R., Salerno-Gonçalves R., Tacket C.O., Levine M.M., Sztein M.B. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 2008, 1:389-398.
25. Salerno-Goncalves R., Wahid R., Sztein M.B. Ex vivo kinetics of early and long-term multifunctional human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vaccine. Clin Vaccine Immunol 2010, 17:1305-1314.
26. Guzman C.A., Borsutzky S., Griot-Wenk M., Metcalfe I.C., Pearman J., Collioud A., et al. Vaccines against typhoid fever. Vaccine 2006, 24:3804-3811.
27. Kantele A., Mäkelä P.H. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine 1991, 9:423-427.
28. Forrest B.D. Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies. J Infect Dis 1992, 166:210-212.
29. Kantele A., Kantele J.M., Savilahti E., Westerholm M., Arvilommi H., Lazarovits A., et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 1997, 158:574-579.
30. Kantele A., Häkkinen M., Moldoveanu Z., Lu A., Savilahti E., Alvarez R.D., et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun 1998, 66:5630-5635.
31. Kantele A., Arvilommi H., Iikkanen K., Savilahti E., Mäkelä H.P., Herzog C., et al. Unique characteristics of the intestinal immune system as an inductive site after antigen reencounter. J Infect Dis 2005, 191:12-17.
32. Pakkanen S.H., Kantele J.M., Moldoveanu Z., Hedges S., Häkkinen M., Mestecky J., et al. Expression of homing receptors on IgA1 and IgA2 plasmablast in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol 2010, 17:393-401.
33. Sigmundsdottir H., Butcher E.C. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008, 9:981-987.
34. Mora J.R., von Andrian U.H. Differentiation and homing of IgA-secreting cells. Mucosal Immunol 2008, 1:96-109.
35. Brandtzaeg P. Update on mucosal immunoglobulin A in gastrointestinal disease. Curr Opin Gastroenterol 2010, 26:554-563.
36. Kantele A., Arvilommi H., Takala R. Immune response to acute diarrhoea seen as circulating antibody secreting cells. J Infect Dis 1988, 158:1011-1016.
37. Kantele J.M., Arvilommi H., Kontiainen S., Salmi M., Jalkanen S., Savilahti E., et al. Mucosally activated circulating human B cells in diarrhea express homing receptors directing them back to the gut. Gastroenterology 1996, 110:1061-1067.
38. Gonzalez A.M., Jaimes M.C., Cajiao I., Rojas O.L., Cohen J., Pothier P., et al. Rotavirus-specific B cells induced by recent infection in adults and children predominantly express the intestinal homing receptor alpha4beta7. Virology 2003, 305:93-105.
39. Berlin C., Berg E.L., Briskin M.J., Andrew D.P., Kilshaw P.J., Holzmann B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993, 74:185-195.
40. Kantele A., Westerholm M., Kantele J.M., Mäkelä P.H., Savilahti E. Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 1999, 17:229-236.
41. Bodhidatta L., Taylor D.N., Thisyakorn U., Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 1987, 9:841-845.
42. Hornick R.B., Greisman S.E., Woodward T.E., DuPont H.L., Dawkins A.T., Snyder M.J. Typhoid fever: pathogenesis and immunologic control. N Engl J Med 1970, 283:686-691.
43. Cox R.J., Brokstad A.K., Zuckerman M.A., Wood J.M., Haaheim L.R., Oxford J.S. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994, 12:993-999.
44. Kantele A. Persistence of diarrheal pathogens is associated with continued recruitment of plasmablasts in the circulation. Clin Dev Immunol 2012, 2012:279206.
45. Fagarasan S., Kinoshita K., Muramatsu M., Ikuta K., Honjo T. In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 2001, 413:639-643.
46. Ferreccio C., Levine M.M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989, 159:766-769.
47. Levine M.M., Ferreccio C., Black R.E., Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987, 1:1049-1052.